Healthcare services company Astrana Health will be reporting results this Thursday afternoon. Here’s what to look for.

Astrana Health beat analysts’ revenue expectations last quarter, reporting revenues of $950.5 million, up 42.9% year on year. It was a strong quarter for the company, with a beat of analysts’ EPS estimates and a solid beat of analysts’ revenue estimates.

Is Astrana Health a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Astrana Health’s revenue to grow 52.6% year on year, in line with the 53.4% increase it recorded in the same quarter last year.

The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Astrana Health has missed Wall Street’s revenue estimates multiple times over the last two years.

Looking at Astrana Health’s peers in the healthcare technology segment, only Omnicell has reported results so far. It exceeded analysts’ revenue estimates, delivering year-on-year sales growth of 14.9%. The stock traded up 14.5% on the results.

There has been positive sentiment among investors in the healthcare technology segment, with share prices up 6.5% on average over the last month. Astrana Health is up 31.7% during the same time and is heading into earnings with an average analyst price target of $36.89 (compared to the current share price of $34.24).

ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.

Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.